Lakefront Biotherapeutics (GLPGF) Capital Expenditures Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn | 39.02% |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | 30.84% |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn | -22.99% |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn | 9.68% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn | 1,133.33% |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 142.64% |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | 53.76% |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 97.31% |
| Dec 31, 2025 | 67.76% |
| Sep 30, 2025 | 28.41% |
| Jun 30, 2025 | -31.55% |
| Mar 31, 2025 | -31.84% |
| Dec 31, 2024 | 71.22% |
| Mar 31, 2024 | 11.18% |
| Dec 31, 2023 | 27.97% |
| Mar 31, 2023 | 55.57% |
| Dec 31, 2022 | 54.94% |
| Mar 31, 2022 | -0.61% |
| Dec 31, 2021 | -22.31% |
| Jun 30, 2021 | -88.39% |
| Mar 31, 2021 | -223.61% |
| Dec 31, 2020 | -104.61% |
| Jun 30, 2020 | -112.14% |
| Mar 31, 2020 | -32.36% |
| Dec 31, 2019 | -108.89% |
| Sep 30, 2019 | -836.03% |
| Jun 30, 2019 | -52.33% |